View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 8, 2021

Ocugen seeks FDA EUA for Covid-19 vaccine use in children

The EUA filing is based on results from a Phase II/III trial that enrolled 526 subjects aged two to 18 years in India.

Ocugen has sought emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its Covid-19 vaccine candidate, BBV152, for use in children in the age group of two to 18 years.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Developed by Ocugen’s partner, India-based Bharat Biotech, and the Indian Council of Medical Research – National Institute of Virology, the whole-virion, inactivated vaccine is called Covaxin.

Covaxin leverages the Vero Cell manufacturing platform, which is used for various paediatric vaccines.

The EUA filing is based on positive data drawn from a Phase II/III clinical trial on 526 children aged two to 18 years.

Carried out between May and July by Bharat Biotech, the multicentre, open-label trial analysed the safety, reactogenicity and immunogenicity of the vaccine in healthy subjects from the age group.

Findings showed that the neutralising antibody responses against the wild-type strain of SARS-CoV-2 in children between the age of two and 18 years were similar to those observed in adult participants aged more than 18 years during the Phase III efficacy and safety trial.

For antibody titers against RBD, S1, N proteins and wild-type neutralising antibodies, more than 90% of the seroconversion rates were reported in this immuno-bridging trial.

Ocugen noted that the data indicates children aged between two and 18 years are protected in the same way as adults above 18 years.

No serious adverse effects were observed in the trial, and all other adverse events recorded were of mild or moderate nature and could be resolved within 24 hours.

Ocugen Board chairman, CEO and co-founder Dr Shankar Musunuri said: “Filing for EUA in the US for paediatric use is a significant step toward our hope to make our vaccine candidate available here and help combat the Covid-19 pandemic.

“The inactivated virus platform has been used for decades in vaccines for the paediatric population and, if authorised, we hope to offer another vaccine option to protect children as young as two years.”

Last week, Bharat Biotech’s Covaxin received Emergency Use Listing from the World Health Organization (WHO) for use in people aged 18 years and above.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology